Antheia announced it has completed a second close of its Series C financing, raising an additional $24 million and bringing the company’s total capital secured over the past year to more than $175 million, when including additional available capital and non-dilutive funding. The advanced biosynthesis company said the broader funding mix includes multiple project agreements with the U.S. government.
The company said it will use the new financing to expand commercial manufacturing capacity, move a pipeline of late-stage biosynthetic pharmaceutical ingredients toward market, and establish U.S. manufacturing operations aligned with national onshoring priorities. Antheia positions its biosynthesis platform as a faster alternative to legacy methods for producing high-value pharmaceutical ingredients, aiming to reduce supply chain risk for global pharmaceutical customers.
The second close was led by ATHOS KG and America’s Frontier Fund, with participation from existing investors including Global Health Investment Corporation and EDBI, which Antheia said co-led the initial Series C close.
Antheia framed the funding as part of a broader push to strengthen pharmaceutical supply chains and increase domestic production. The company pointed to recent milestones in 2024 and 2025, including its first commercial delivery of thebaine, an ingredient used to produce Narcan, as well as two U.S. government project agreements focused on onshoring pharmaceutical supply chains. It also cited a strategic partnership announced in November 2025 with TAPI to further commercialize its pipeline.
Antheia said its technology has drawn attention from U.S. government stakeholders as a priority capability for public health, national security, and economic security, and that the company intends to scale production while advancing additional ingredients and applications through its platform.
KEY QUOTES
“Advanced biosynthesis has immense potential to transform pharmaceutical supply chains and unlock a new era of innovative medicines. Building on the success of our Series C, this additional infusion of capital will fuel our efforts to address urgent supply chain vulnerabilities and more broadly, lead a paradigm shift for pharmaceutical manufacturing.”
Dr. Christina Smolke, CEO and Co-Founder, Antheia
“America’s Frontier Fund invests in companies that strengthen U.S. industrial leadership and secure critical supply chains. Antheia is redefining how essential medicines are made by combining advanced biosynthesis with scalable domestic manufacturing. This approach addresses longstanding shortages, long lead times, and geopolitical risk. We are excited to support Antheia as it builds a more resilient and secure U.S. pharmaceutical ecosystem.”
Jeff Karras, General Partner, America’s Frontier Fund
